# A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

> **NCT00190775** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 502 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** Atomoxetine Hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00190775
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2009-07
- **Final completion:** 2009-10
- **Target enrollment:** 502 (ACTUAL)
- **Last updated:** 2011-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00190775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00190775, "A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00190775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*